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ABSTRACT
Objective: Clindamycin is the drug of choice for the treatment of severe form of skin, soft tissue, and blood infections caused by resistant Staphylococcus 
aureus in the form of methicillin-resistant S. aureus (MRSA) and erythromycin-resistant S. aureus. In this research, we determine the susceptibility 
pattern of isolated S. aureus strains against antibiotics and the prevalence of resistant S. aureus in the form of MRSA, inducible clindamycin-resistant 
S. aureus (inducible macrolide-lincosamide-streptogramin B [iMLSB]) and constitutive clindamycin-resistant S. aureus (cMLSB).
Methods: A total of 310 isolated S. aureus among 2000 different clinical samples were subjected to oxacillin (1 µg) as per the Kirby-Bauer disk 
diffusion method for MRSA. Clindamycin-resistant either in the form of iMLSB or cMLSB was determined through double disk diffusion method or 
D-test by use erythromycin (2 µg) and clindamycin (15 µg) as per the CLSI guidelines.
Results: Out of total S. aureus, MRSA and methicillin-sensitive S. aureus (MSSA) were 78.06% and 20.64%, respectively. This study showed that iMLSB 
and cMLSB were 34.19% and 23.22%. Both iMLSB and cMLSB were found more among MRSA than MSSA (43.80%, 26.85% and 40.62%, 10.93%), 
respectively.
Conclusion: This study helps for the characterization of different resistant strains of S. aureus along with the determination of the prevalence rate of 
these mutant forms causing nosocomial infections.
Keywords: Methicillin-resistant Staphylococcus aureus, Methicillin sensitive Staphylococcus aureus, Inducible macrolide-lincosamide-streptogramin 
B and constitutive macrolide-lincosamide-streptogramin B, Erythromycin, Oxacillin, Clindamycin.
INTRODUCTION
Staphylococcus aureus is recognized as the causative agent of skin, soft 
tissue, and systemic infection. It frequently associated with the pus 
formation in different body sites infections. It is also more common 
nosocomial as well as opportunistic pathogens [1]. It causes different 
types of diseases such as skin infections, rhinitis, otitis media infection, 
mastitis, suppurative wounds osteomyelitis, urinary tract infections, 
and septic arthritis with life-threatening invasion diseases such as 
pneumonia, septicemia, endocarditis, bacteremia, and toxic shock 
syndrome [2].
Origin of methicillin-resistant S. aureus (MRSA) made serious problems 
for the treatment and selection of therapeutics available alternatives 
for staphylococcal infections [3]. Earlier staphylococcal infections 
have been treated by the use of erythromycin since three–four decades 
and become resistant against it has been reported since long [4]. The 
increase of resistant staphylococcal infection with MRSA has led to 
renewed interest in the use of macrolide-lincosamide-streptogramin B 
(MLSB) antibiotics for the treatment of such infections [5]. These family 
MLSB antibiotics with clindamycin are the preferred antibiotic due to 
its best pharmacokinetics property [6].
Macrolides (erythromycin, clarithromycin, and roxithromycin) 
resistance may be constitutive and inducible in the presence of a 
macrolide inducer being the most common erythromycin [7]. It is the 
best inducer for the synthesis of erythromycin ribosome methylase 
(erm) enzyme. In inducible clindamycin resistance S. aureus (iMLSB), 
erm enzyme only produced in the presence of erythromycin whereas 
in constitutive phenotype (constitutive clindamycin-resistant S. aureus 
The double disk diffusion test (D-test) is used to distinguished inducible 
clindamycin resistance from constitutive clindamycin-resistant 
S. aureus among erythromycin-resistant isolates to determine 
therapeutic for clindamycin to be used as a therapeutic option [9].
In this present research, we aimed to determine the prevalence of 
MLSBi and MLSBc among hospital-based isolates of S. aureus in the 
form of MRSA and methicillin-sensitive S. aureus (MSSA).
METHODS
This research included 2000 different clinical samples; pus, blood, 
urine, sputum, throat swab, pleural fluid, synovial fluid, ascitic fluid, ear 
swab, cerebrospinal fluid, stool, and high vaginal swab and processed 
in National Medical College and Teaching Hospital, Birgunj, Nepal from 
February 2017 to December 2017. Among these, samples 310 (15.5%) 
S. aureus was isolated by growth on blood agar, nutrient agar, and 
mannitol salt agar. These isolates were confirmed by use catalase and 
coagulase test as per the standard operative procedure CLSI [10].
MRSA was identified by the oxacillin disk diffusion method. In this 
method, 0.5 MacFarland standard inoculums of S. aureus was inoculated 
on Muller-Hinton agar (MHA) media through swabbing and left for 1 h. 
The oxacillin disc (1 µg) was now put on inoculated MHA media and 
incubated at 37°C for 24 h. By the measurement of the zone of diameter, 
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[cMLSB])  the  erm enzyme naturally  produced without  the  presence 
of  inducer.  When  this  enzyme  produced  through  erm  gene  induced 
confers  cross  resistant  to  other  members  of  group  including 
lincosamide and streptogramin B [8].
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≥13 mm, 11–12 mm, and ≤10 mm around oxacillin disc was considered 
oxacillin susceptible, intermediate, and resistant, respectively [10].
iMLSB and cMLSB were identified by the use of erythromycin (15 μg) 
and clindamycin (2 μg) disks through D-test. In this test 0.5, MacFarland 
standard inoculums of S. aureus were swabbed on the surface of MHA 
media. The erythromycin and clindamycin disks were placed at a 
distance of 15–20 mm distant edge to edge from each other incubated 
at 37°C for 24 h. Through the observation as flattening of the zone 
of inhibition around the clindamycin proximal to erythromycin disk 
(D shaped zone of inhibition) indicated as iMLSB phenotypes. There no 
formation of any zone of inhibition around both antibiotic disks that 
was defined as cMLSB phenotypes [11].
RESULTS
Two thousand different clinical samples were processed and the patient 
samples distribution shown in Fig. 1. Out of total samples, 310 (15.50%) 
S. aureus were isolated and identified from different samples (Table 1). 
Among S. aureus, MRSA, MSSA, iMLSB, and cMLSB were selected 
as 242 (78.06%), 64 (20.64%), 106 (34.19%), and 72 (23.22%), 
respectively (Fig. 2). MRSA and cMLSB were found more in blood. MSSA 
and iMLSB were higher in pus than other clinical samples (Fig. 3). Out 
of total MRSA, 106 (43.80%) strains were iMLSB and 65 (26.85%) were 
cMLSB whereas among MSSA, 26 (40.62%) S. aureus were iMLSB and 
7 (10.93%) were cMLSB (Fig. 4).
DISCUSSION
Empirical therapy for staphylococcal infection has become more limited 
due to the emergence and the prevalence of MRSA. Among options 
available for the treatment of MRSA and MSSA, clindamycin is one of 
the good alternatives [6]. However, therapeutic failure caused by iMLSB 
strains is now being reported commonly.
It was also observed that the prevalence of iMLSB and cMLSB was 
higher among MRSA (43.80% and 26.85%, respectively) as compared to 
MSSA (40.62% and 10.93%). This was in concordance with Yilmaz et al. 
who found 24.4% iMLSB among MRSA and 14.8% among MSSA [16]. 
Rahabar and Hajia reported 22.6% iMLSB among MRSA and 4% in 
MSSA [17].
In one study, all iMLSB shown resistance against macrolides and made 
either low-level resistance or susceptibility to clindamycin without 
induction by the use of erythromycin but with induction MICs of 
clindamycin were noted as an increase from 16 to 256 g/ml in iMLSB 
indicating inducible resistant [18]. Staphylococci making inducible 
Table 1: Sample wise isolation and identification of S. aureus
Clinical samples Number of samples S. aureus
Ascitic fluid 7 1
Ear swab 4 0
Blood 529 155
Cerebrospinal fluid 65 1
Pus 488 146
Pleural fluid 21 2
Synovial fluid 8 1
Sputum 136 1
Stool 23 0
Throat swab 8 1
Urine 636 2
High vaginal swab 75 0
Total 2000 310
S. aureus: Staphylococcus aureus
Fig. 1: Distribution of clinical samples. CSF: Cerebrospinal fluid, 
HVS: High vaginal swab
Fig. 2: Selection of resistant strains of Staphylococcus aureus
Fig. 3: Distribution of resistant strains of Staphylococcus aureus 
among clinical samples
Fig. 4: Selection of inducible macrolide-lincosamide-
streptogramin B and constitutive clindamycin-resistant S. aureus 
among methicillin-resistant S. aureus and methicillin-sensitive 
S. aureus
We found a high prevalence of 78.06% and 20.64% of MRSA and MSSA 
among all staphylococcal isolates. A study conducted in Nepal, 
the prevalence of MRSA was observed as 19% [12]. Majumder et al. 
from  Assam  found  52.9%  MRSA  [13].  In  our  study  found 
34.19% iMLSB isolates than 23.22% cMLSB. A similar study 
conducted in Turkey observed a prevalence of iMLSB as 21.9% [14].
 Ravisekhar et al. found 21% iMLSB isolates [15].
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resistance to MLS antibiotics are now common to clinical practice, 
especially in developing countries. There should be cautious for using 
the clindamycin in a severe case of infections due to making constitutive 
mutants during the course of clindamycin therapy in patients with 
iMLSB [19].
At present, some authors suggested less or no use of clindamycin 
for serious infections with high burden bacteria such as abscess or 
osteomyelitis [20]. Conversely, all erythromycin-resistant S. aureus was 
labeled as clindamycin resistant would prevent the use of clindamycin 
in infections caused by clindamycin-susceptible isolates. Clindamycin is 
now mostly used in non iMLSB or less severe form of infections caused 
by S. aureus.
CONCLUSION
Although the prevalence rate may differ from hospital to hospital, this 
study reflects characterization and prevalence of MRSA, MSSA, iMLSB, 
and cMLSB strains through oxacillin disk diffusion and the D-test 
at tertiary care hospital. Microbiologists should conform for theses 
mutants strains among S. aureus isolates.
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